Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial

被引:2
|
作者
Matsuura, Nozomi [1 ]
Kanayama, Masaya [1 ]
Watanabe, Yuta [1 ]
Yamada, Hirokazu [2 ,3 ]
Lili, Loukia [4 ]
Torii, Akira [5 ]
机构
[1] Kirin Holdings Co Ltd, Inst Hlth Sci, Hlth Sci Business Div, Fujisawa, Kanagawa 2518555, Japan
[2] Soiken Inc, Tokyo, Tokyo 1010052, Japan
[3] EviPRO Co Ltd, Tokyo, Tokyo 1010032, Japan
[4] Thorne HealthTech Inc, New York, NY 10019 USA
[5] Torii Med Clin, Tokyo, Tokyo 1570066, Japan
关键词
irritable bowel syndrome; personalized; microbiome; prebiotics; probiotics; PLACEBO-RESPONSE RATE; DOUBLE-BLIND; GUT MICROBIOTA; SEVERITY; LACTOBACILLUS; JAPANESE;
D O I
10.3390/nu16193333
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background/Objectives: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients. Methods: Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4. Results:The IBS-severity scoring system significantly decreased in all patients (-38.0 [95% confidence interval (CI): -53.6, -22.4]; p < 0.001), in patients with IBS-D (-44.5 [95% CI: -70.6, -18.5]; p = 0.004) and IBS-C (-51.2 [95% CI: -79.4, -22.9]; p = 0.002), but not in those with IBS-M (-20.0 [95% CI: -48.0, 8.1]; p = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention. Conclusions: In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Efficacy of Jawarish Shahi a herbal formulation in irritable bowel syndrome: An open-labeled single-arm clinical trial
    Moazzam, Shehanshah Wali
    Mobeen, Abdul
    Siddiqui, Mansoor Ahmad
    JOURNAL OF TRADITIONAL AND COMPLEMENTARY MEDICINE, 2022, 12 (06): : 529 - 535
  • [2] Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome: a prospective, open-label, and single-arm study
    Matsueda, Kei
    Fukudo, Shin
    Ogishima, Masayuki
    Naito, Yuki
    Nakamura, Soichiro
    BIOPSYCHOSOCIAL MEDICINE, 2024, 18 (01)
  • [3] Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome: a prospective, open-label, and single-arm study
    Kei Matsueda
    Shin Fukudo
    Masayuki Ogishima
    Yuki Naito
    Soichiro Nakamura
    BioPsychoSocial Medicine, 18
  • [4] An Open-Label Trial Study of Quality-of-Life Assessment in Irritable Bowel Syndrome and Their Treatment
    Alexandru, Bogdana Ariana
    Rat, Lavinia Alina
    Moldovan, Andrada Florina
    Mihancea, Petru
    Maris, Lavinia
    MEDICINA-LITHUANIA, 2022, 58 (06):
  • [5] Prescript-Assist™ probiotic-prebiotic treatment for irritable bowel syndrome:: An open-label, partially controlled, 1-year extension of a previously published controlled clinical trial
    Bittner, Alvah C.
    Croffut, Robert M.
    Stranahan, Mary C.
    Yokelson, Titut N.
    CLINICAL THERAPEUTICS, 2007, 29 (06) : 1153 - 1160
  • [6] Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome A Randomized Clinical Trial
    Nurko, Samuel
    Saps, Miguel
    Kossowsky, Joe
    Zion, Sean Raymond
    Di Lorenzo, Carlo
    Vaz, Karla
    Hawthorne, Kelsey
    Wu, Rina
    Ciciora, Steven
    Rosen, John Michael
    Kaptchuk, Ted J.
    Kelley, John M.
    JAMA PEDIATRICS, 2022, 176 (04) : 349 - 356
  • [7] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
    Song, Zhengbo
    Lou, Guangyuan
    Wang, Yina
    Yang, Zhiping
    Wang, Wenxian
    Ji, Yongling
    Chen, Shiqing
    Xu, Chunwei
    Hu, Xiao
    Zhang, Yiping
    BMC MEDICINE, 2022, 20 (01)
  • [8] Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial
    Lembo, Anthony
    Kelley, John M.
    Nee, Judy
    Ballou, Sarah
    Iturrino, Johanna
    Cheng, Vivian
    Rangan, Vikram
    Katon, Jesse
    Hirsch, William
    Kirsch, Irving
    Hall, Kathryn
    Davis, Roger B.
    Kaptchuk, Ted J.
    PAIN, 2021, 162 (09) : 2428 - 2435
  • [9] A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer
    Xu, Jianming
    Bai, Yuxian
    Sun, Huichuan
    Bai, Chunmei
    Jia, Ru
    Li, Yi
    Zhang, Wenjie
    Liu, Lei
    Huang, Cheng
    Guan, Mei
    Zhou, Jinghong
    Su, Weiguo
    CANCER, 2021, 127 (21) : 3975 - 3984
  • [10] Randomized clinical trial: Effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome
    Stevenson, Cheryl
    Blaauw, Renee
    Fredericks, Ernst
    Visser, Janicke
    Roux, Saartjie
    NUTRITION, 2014, 30 (10) : 1151 - 1157